17628 Federal Register / Vol. 62, No. 69 / Thursday, April 10, 1997 / Notices

• Development of improved

derivatives of minocycline.

Party Contributions

The role of NIA includes the

following:

(1) Develop and file, in consultation

with Collaborator, any and all regulatory

applications for the use of minocycline

in the treatment of osteoporosis;

(2) Provide staff, expertise, and

materials for the development and

execution of protocols, and for the

development and testing of promising

minocycline analogues;

(3) Together with the Collaborator,

evaluate the results of joint research,

and to ensure progress toward meeting

the CT–CRADA goals; and

(4) Provide work space and

equipment for testing of any prototype

pharmaceutical compositions

developed.

The role of the successful Collaborator

will include the following:

(1) Provide staff, expertise, and

materials for the development and

production of pharmaceutical

compositions;

(2) Purchase or manufacture an

adequate supply of minocycline;

(3) Together with NIA, evaluate the

results of joint research, and to ensure

progress toward meeting the CT–

CRADA goals;

(4) Provide funding in support of the

clinical trials; and

(5) Provide resource to develop and

market any promising analogues to

minocycline.

Selection Criteria

Proposals submitted for consideration

should fully address each of the

following qualifications:

(1) Expertise

The successful Collaborator should

have the following expertise:

A. Demonstrated expertise in

developing and producing high quality

pharmaceutical compositions;

B. Demonstrated ability to secure

national and/or international marketing

and distribution of pharmaceutical

compositions;

C. Demonstrated expertise in

overseeing all aspects of product

development;

D. Demonstrated intellectual ability to

guide development of product line

which addresses the requirements of

NIA.

(2) Reputation

The successful Collaborator should be

recognized in the pharmaceutical

industry for each of the following:

A. Producing quality pharmaceutical

products;

B. Indications of high levels of

satisfaction by industry experts with the

Collaborator’s products; and

C. Strong commitment to the research

and development of new

pharmaceuticals.

(3) Physical Resources

The successful Collaborator should be

able to demonstrate it will have the

following material resources as of the

commencement of research under the

CT–CRADA:

A. An established headquarters with

offices, space, and equipment;

B. Adequate means for

communication with the Collaborator

during business hours, such as by

telephone, mail, e-mail, the Internet,

and other evolving technologies; and

C. Sufficient financial resources to

support, at a minimum, the current

activities of the CT–CRADA to meet the

needs of NIA.

Dated: March 26, 1997.

Thomas D. Mays,

Director, Office Technology Development,

National Cancer Institute, NIH.

[FR Doc. 97–9239 Filed 4–9–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Child Health and

Human Development; Notice of Closed

Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

National Institute of Child Health and

Human Development Special Emphasis

Panel (SEP) meeting:

Name of SEP: Specialized Clinical

Fellowships (Teleconference).

Date: May 5, 1997.

Time: 1:00 p.m.—adjournment.

Place: 6100 Executive Boulevard, 6100

Building Room 5E03, Rockville, Maryland

20852.

Contact Person: Hameed Khan, Ph.D.,

Scientific Review Administrator, NICHD,

6100 Executive Boulevard, 6100 Building,

Room 5E01, Rockville, Maryland 20852,

Telephone: 301–496–1485.

Purpose/Agenda: To evaluate and review

grant applications.

The meeting will be closed in accordance

with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The

discussions of these applications could

reveal confidential trade secrets or

commercial property such as patentable

material and personal information

concerning individuals associated with the

applications, the disclosure of which would

constitute a clearly unwarranted invasion of

personal privacy.

(Catalog of Federal Domestic Assistance

Program Nos. [93.864, Population Research

and No. 93.865, Research for Mothers and

Children, National Institutes of Health].)

Dated: April 7, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–9297 Filed 4–9–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Neurological

Disorders and Stroke, Division of

Extramural Activities; Notice of Closed

Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting:

Name of Committee: National Institute of

Neurological Disorders and Stroke Special

Emphasis Panel (Telephone Conference Call).

Date: April 23, 1997.

Time: 9:00 a.m.

Place: National Institutes of Health, 7550

Wisconsin Avenue, Room 9C10, Bethesda,

MD 20892.

Contact Person: Dr. Howard Weinstein/Mr.

Phillip Wiethorn, Scientific Review

Administrator, National Institutes of Health,

7550 Wisconsin Avenue, Room 9C10,

Bethesda, MD 20892, (301) 496–9223.

Purpose/Agenda: To review and evaluate

an SBIR Phase II Contract Proposal.

The meeting will be closed in accordance

with the positions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

Applications and/or proposals and the

discussions could reveal confidential trade

secrets or commercial property such as

patentable material and personal information

concerning individuals associated with the

applications and/or proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

This notice is being published less than 15

days prior to the meeting due to the urgent

need to meet timing limitations imposed by

the review and funding cycle.

(Catalog of Federal Domestic Assistance

Program No. 93.853, Clinical Research

Related to Neurological Disorders; No.

93.854, Biological Basis Research in the

Neurosciences).

Dated: April 7, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–9298 Filed 4–9–97; 8:45 am]

BILLING CODE 4140–01–M